Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Case You Missed It: Top 10 "Gray Sheet" Stories In August

This article was originally published in The Gray Sheet

Executive Summary

Our feature exploring the myriad complications of the ongoing revision process for the international device quality systems standard ISO 13485 attracted the most "Gray Sheet" Web traffic by a long shot last month. Also popular: stories on a gap in warning letter postings; a Google device spinoff; China device reforms; and more.

You may also be interested in...

Latest FDA Crackdown On Duodenoscope Makers Includes Warning Letters, 510(k) Status Alerts

FDA takes new enforcement actions against duodenoscope makers in Aug. 12 warning letters to Fujifilm Medical Systems, Hoya and Olympus Medical Systems, charging adulterations to scopes, and noting troubles with CAPAs and reprocessing validation activities. Meanwhile, Fujifilm and Hoya also received so-called "510(k) status" letters.

Off-Label Promotion Ruling Increases Pressure For FDA Policy Change

Amarin Corp. PLC's First Amendment legal victory on Vascepa (icosapent ethyl) may intensify pressure on FDA to develop new guidance and regulations governing off-label promotion before its hand is further forced by more adverse court rulings and Congress.

PMA Approvals On Track For 15-Year High

The agency has so far approved a total of 36 original PMAs and panel-track supplements in 2015, the highest total at this point in the year since 2001.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts